Bristol Myers' $14 billion schizophrenia drug is not working out, Bloomberg reports. The acquisition aimed to transform treatment for the mental health condition.
Bristol Myers Squibb's $14 billion acquisition of a neuroscience drug intended to revolutionize schizophrenia treatment is not progressing as hoped, Bloomberg reports.
What happened
Bristol Myers Squibb's $14 billion acquisition of a neuroscience drug intended to revolutionize schizophrenia treatment is not progressing as hoped, Bloomberg reports.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
Hubs
Briefings
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.